Colorectal Cancer

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

In an effort to improve colorectal cancer screening rates via a less invasive method, the registrational ECLIPSE is evaluating the performance of the LUNAR-2 blood test in detecting colorectal cancer in average-risk adults.

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.